Global Prednisolone Market Size, Share, and COVID-19 Impact Analysis, By Formulation (Oral Solution and Tablets), By Indications (Inflammatory Conditions, Allergies, Autoimmune Disorders, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Prednisolone Market Insights Forecasts to 2033

• The Global Prednisolone Market Size was estimated at USD 0.145 Billion in 2023
• The Market Size is expected to Grow at a CAGR of around 8.10% from 2023 to 2033
• The Worldwide Prednisolone Market Size is expected to reach USD 0.316 Billion by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Prednisolone Market Size is anticipated to exceed USD 0.316 Billion by 2033, growing at a CAGR of 8.10% from 2023 to 2033.

Market Overview

The prednisolone market involves the development, production, and commercialization of prednisolone, a synthetic corticosteroid that is used in the management of inflammatory conditions, allergies, asthma, autoimmune disorders, and certain types of cancer. Prednisolone is a corticosteroid used to treat various health issues, including allergies, blood disorders, skin diseases, inflammation, infections, and several types of cancers. Prednisolone targets the immune system to relieve swelling, redness, itching, and allergic reactions. Prednisolone is a glucocorticoid, reducing the oxo group at position 11 to the corresponding beta-hydroxy group. It has various roles as an adrenergic agent, anti-inflammatory drug, antineoplastic agent, immunosuppressive agent, drug metabolite, environmental contaminant, and xenobiotic. Oral prednisolone is commonly prescribed for acute exacerbations of asthma in older children and adults and acute preschool viral wheeze. It can be taken as tablets or liquid, usually taken once or twice a day, with or without food. Prednisolone is developed to block the action of endothelin, a natural substance that narrows blood vessels, improving blood flow and reducing strain on the heart and lungs. It is primarily prescribed for treating pulmonary arterial hypertension, a condition where high blood pressure in the lungs makes it difficult for the heart to pump blood efficiently. Prednisolone is used in the management of autoimmune hepatitis. The marketed products of prednisolone are HEALTHY-PRED-20 tablets, Predkab-Forte Syrup, PredGrev ophthalmic suspension, etc.

The rising prevalence of autoimmune hepatitis accelerates the need for immunosuppressive drugs such as prednisolone for treating autoimmune hepatitis resulting in the expansion of the market. For instance, the data published in the Journal, Clinical and Molecular Hepatology reveals that autoimmune hepatitis (AIH) is a chronic and progressive liver disease caused by the body's immune system attacking the liver, causing swelling, irritation, and damage. The exact cause is unknown, but genetic and environmental factors interact over time to trigger the disease. Middle-aged individuals between 50 and 60 years old are most susceptible to AIH, and women are more susceptible. AIH results in hepatocellular damage, possibly induced by uncontrolled autoreactive CD4 and CD8 T cells. The disease is characterized by elevated serum aminotransferase and immunoglobulin G (IgG) levels and the detection of autoantibodies. The annual incidence rate of AIH worldwide is 1.37 per 100,000 people, with a male-to-female ratio of 1:5. The prevalence rate, which varies by area, is 17.44 per 100,000 people. The mid-50s is the typical age at which it first appears.

The growing cases of uveitis (inflammation in the eye), drive the demand for ophthalmic suspensions and eyedrops of prednisolone which results in the market growth. For instance, the data disclosed in the Journal, Frontiers in Medicine indicates the epidemiology and risk factors of non-infectious uveitis, a leading cause of vision loss in the developed world. It includes systemic autoimmune diseases and localized autoimmune diseases and can be caused by HLA-B27-associated anterior uveitis, Fuchs uveitis syndrome, and sarcoidosis. In the developed world, it accounts for 10-15% of all blindness cases. Non-infectious uveitis prevalence in the U.S. is 121/100,000, with females and the working age group being most affected. Smoking and vitamin D deficiency are the leading risk factors.

Several government initiatives drive the market growth. For example, The National Programme for Health Care of the Elderly (NPHCE) addresses arthritis among the elderly, offering free or subsidized treatment in government hospitals. Affordable Medicines and Reliable Implants for Treatment (AMRIT) Deendayal outlets have been opened at over 200 institutions/hospitals to provide discounted drugs and implants. Jan Aushadhi stores provide generic drugs at affordable prices. The Pradhan Mantri Jan Arogya Yojna (PMJAY) provides cashless access to services in listed hospitals across India to over 10 crore beneficiary families. Considering the idealistic features of prednisolone such as a broad range of clinical applications and government initiatives propels the market growth and is anticipated to exceed USD 0,316 billion by 2033.

Report Coverage

This research report categorizes the global prednisolone market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global prednisolone market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global prednisolone market.

Driving Factors:

The increasing proportion of the geriatric population:

The biological process of aging is marked by the buildup of cellular and molecular damage, which lowers an individual's mental and physical abilities and raises the likelihood of illness and death. Although older people are more likely to acquire chronic and inflammatory diseases such as arthritis, asthma, and autoimmune disorders, they represent a substantial market driver for prednisolone. Prednisolone is a vital treatment choice for the elderly considering these medical conditions frequently need long-term care. Age-related alterations in the immune system can be caused by a persistent pro-inflammatory state and chronic inflammation. The proportion of the world's population 60 and older is predicted to double by 2050, with one in six individuals being 60 or older by 2030.

Rising prevalence of inflammatory conditions:

Inflammatory diseases, including, rheumatoid arthritis and asthma, are pathological conditions affecting various organs and tissues. The growth of the prednisolone market is driven by these diseases due to its potent anti-inflammatory and immunosuppressive properties. Prednisolone is widely used to manage chronic inflammatory disorders, which are the most significant cause of death worldwide and are ranked as the greatest threat to human health by the WHO.

Restraining Factors

The availability of alternative medications, side effects associated with extended use of prednisolone headache, nausea, dizziness, and behavior changes, stringent regulatory framework, lack of awareness in the low middle-income countries, and high cost of branded prednisolone drugs may impede the market growth.

Market Segmentation

The global prednisolone market share is classified into formulation and indications.

• The tablets segment dominated the global prednisolone market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the formulation, the global prednisolone market is categorized into oral solution and tablets. Among these, the tablets segment dominated the global prednisolone market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is attributed to cost-effectiveness, patient convenience, greater physical and chemical stability, minimized risk of microbial contamination, longer shelf life, availability in the novel drug delivery system such as controlled drug delivery system, precise dosing, ease of administration, and rapid dissolution of drug and faster absorption.

• The allergies segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global prednisolone market is categorized into inflammatory conditions, allergies, autoimmune disorders, and others. Among these, the allergies segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is attributed to the increasing prevalence of allergic conditions, alleviates symptoms such as redness and itching, reduces inflammation, is effective against severe allergies, and extensive used by the adults and aged population for the management of the allergies.

Regional Segment Analysis of the Global Prednisolone Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global prednisolone market over the predicted timeframe.

North America is anticipated to hold the largest share of the global prednisolone market over the predicted timeframe. The rising incidence of chronic illnesses and the need for corticosteroid treatments are driving expansion in the prednisolone market in North America. The region's notable healthcare spending and sophisticated research capabilities bolster its market position. Significant pharmaceutical firms and intensive research and development initiatives are anticipated to maintain market expansion. The synthetic corticosteroid prednisolone is used extensively because of its immunosuppressive and anti-inflammatory qualities. The market is being driven by the aging population, improvements in healthcare infrastructure, and rising knowledge of its medicinal benefits. Patient compliance and treatment results are being improved via formulation advancements such as combination therapies and sustained-release tablets. A wider range of patients can now obtain prednisolone owing to the availability of affordable generic variants.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The increasing disposable income, improved healthcare infrastructure, and growing awareness about healthcare constitute several of the variables driving market growth. The industry is mostly driven by nations like China, Japan, and India, which have sizable populations of older individuals and a rising incidence of chronic illnesses. The market expansion in this area is facilitated by the growing healthcare facilities and government programs to improve healthcare affordability and accessibility. Increased bioavailability and sustained release are two formulation innovations that are improving the efficacy and patient experience of prednisolone. Prednisolone is getting more widely available as a result of Asia-Pacific's growing manufacturing pharmaceutical companies, which is made possible by skilled workers and affordable prices. Strategic partnerships are being formed by pharmaceutical companies to increase their market share and enhance drug accessibility in the area.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global prednisolone market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AbbVie Inc.
• Mylan N.V.
• Sandoz International GmbH
• Hikma Pharmaceuticals PLC
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Amneal Pharmaceuticals, Inc.
• Bayer AG
• AstraZeneca plc
• Torrent Pharmaceuticals
• Sanofi S.A.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In October 2024, Lupin, a global pharmaceutical company launched the first generic version of the Pred Forte (Prednisolone Acetate) ophthalmic suspension USP, 1% in the United States. Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic version of Pred Forte Ophthalmic Suspension, 1% of AbbVie, Inc., used to treat steroid-responsive inflammation in the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, with estimated annual sales of USD 198 million in the U.S.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global prednisolone market based on the below-mentioned segments:

Global Prednisolone Market, By Formulation

• Oral Solution
• Tablets

Global Prednisolone Market, By Indications

• Inflammatory Conditions
• Allergies
• Autoimmune Disorders
• Others

Global Prednisolone Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa